ENTITY: BRITISH AMERICAN TOBACCO PLC

MACRO INTELLIGENCE MEMO: NAVIGATING TERMINAL DECLINE IN LEGACY TOBACCO BUSINESS

From: The 2030 Report Date: June 2030 Re: BAT Leadership Strategy - Managing Orderly Decline While Investing in Smoke-Free Transition

EXECUTIVE SUMMARY

The CEO of British American Tobacco between 2024-2030 faced perhaps the most existentially challenging leadership position in the sample: managing a business fundamentally declining in its core market while attempting to transition to new products before the decline became unmanageable. By June 2030, the CEO had successfully navigated this transition, maintaining profitability and dividends while investing in smoke-free alternatives, though the fundamental challenge remained unsolved: the traditional cigarette business continued declining faster than smoke-free alternatives could grow to replace it.

The memo examines the strategic decisions, organizational pressures, and long-term implications of BAT's management of terminal decline between 2024-2030, offering insights relevant to any legacy business confronting structural industry disruption.

SUMMARY: THE BEAR CASE vs. THE BULL CASE

BEAR CASE (BASE CASE): Managed Decline with Traditional Cigarette Focus

Assumptions: BAT continues maintaining cigarette business while modestly investing in smoke-free (£4-5B cumulative 2024-2030). Smoke-free reaches 15-20% of revenue by 2030. Cigarette business declines 3-4% annually. Dividend maintained through cost cuts but growth limited.

2030-2035 Projections (Bear Case): - Revenue (2035): £30-32B (continued decline) - Smoke-Free Revenue (2035): £6-8B (20-25% of total) - Dividend per Share (2035): £0.45-0.50 (flat to slight decline)

BULL CASE: Aggressive Smoke-Free Pivot + Cost Restructuring

Assumptions: CEO commits £8-10B (vs. £4-5B bear case) to accelerated smoke-free buildout 2024-2030. Divests lowest-margin cigarette markets. Aggressive cost reduction targets 22-27% headcount reduction. Smoke-free reaches 35-40% of revenue by 2030; 50%+ by 2035.

2030-2035 Projections (Bull Case): - Revenue (2035): £28-32B (decline slowed through smoke-free acceleration) - Smoke-Free Revenue (2035): £14-16B (50%+ of total) - Operating Margin (2035): 38-42% (vs. 35-37% bear case through restructuring) - Dividend Sustainability: Higher confidence through cost discipline

SECTION 1: THE FUNDAMENTAL DILEMMA - MANAGING DECLINE

The Core Business Paradox

In 2024, BAT's CEO confronted a classic "innovator's dilemma" scenario, with unusual urgency:

The Paradox: 1. Core Business Generates Enormous Cash: Traditional cigarette business generates $8-10 billion in annual operating profit (approximately 45-50% operating margin on $18-20 billion cigarette revenue) 2. Core Business is Declining: Cigarette volumes decline 3-5% annually in developed markets as smoking rates fall (due to health awareness, regulation, and social stigma) 3. Replacement Business is Uncertain: Smoke-free products (heated tobacco, nicotine pouches, vaping) are growing but not fast enough to replace cigarette profit in foreseeable future 4. Long-term Viability Unknown: If trends continue, cigarette business becomes too small to fund dividends by 2035-2040

The CEO's Strategic Choice: Rather than aggressive cost-cutting in the declining cigarette business (which would accelerate decline and damage brand), the CEO chose to: 1. Milk the declining business for cash (maintain pricing, minimize cost cuts) 2. Invest aggressively in smoke-free alternatives ($8-10 billion 2024-2030) 3. Maintain investor confidence through dividends 4. Hope that smoke-free products would eventually become material portion of profits

This required patience, discipline, and tolerance for short-term financial "inefficiency" (investing in uncertain smoke-free growth while milking declining cigarette business).

The Shareholder Pressure Dimension

The CEO faced constant shareholder pressure pulling in contradictory directions:

Income-Focused Shareholders (65-70% of shareholder base): - Primarily retired individuals or pension funds seeking reliable dividend income - Demanded steady/growing dividends to support retirement - Preferred cost-cutting and buybacks (which supported stock price) over uncertainty of smoke-free transition - Messaging: "Cut costs, maximize cash, return to shareholders"

Growth-Focused Investors (15-20% of shareholder base): - ESG-focused institutional investors uncomfortable with cigarette business fundamentally - Demanded faster transition to smoke-free, or exit - Pressure: "Why are we in tobacco? Why not sell and invest in healthcare?"

Stabilization-Focused Investors (10-15% of shareholder base): - Long-term value investors believing transition would succeed over time - Supported CEO's strategy of measured investment in smoke-free while maintaining dividends - Advice: "Stay the course, patience will be rewarded"

The CEO's strategy required satisfying income investors (through dividends) while investing in smoke-free (to satisfy growth/ESG investors). This balance was delicate and required masterful investor communication.

SECTION 2: THE SMOKE-FREE BET

Investment Trajectory and Capital Allocation

Between 2024-2030, BAT allocated approximately $8-10 billion to develop and market smoke-free products:

Capital Allocation by Category (Estimated):

R&D and Product Development: $2.0-2.5 billion - Heated tobacco device engineering (refining Glo brand technology) - Nicotine pouch formulation and manufacturing - Vaping device development and regulation - Regulatory and scientific support

Marketing and Brand Building: $3.0-3.5 billion - Consumer advertising in regulated markets - Digital marketing and direct-to-consumer campaigns - Point-of-sale marketing - Influencer and content partnerships

Manufacturing Infrastructure: $1.5-2.0 billion - Factories for nicotine pouches and other products - Supply chain infrastructure - Distribution network expansion

Mergers, Acquisitions, and Partnerships: $1.5-2.0 billion - Acquisitions of smaller smoke-free brands - Partnerships with emerging companies - Joint ventures in high-growth markets

The Smoke-Free Portfolio by 2030

By June 2030, BAT's smoke-free portfolio included:

Heated Tobacco (Glo Brand): - Volume: Approximately 140-160 billion sticks equivalent annually (still below peak of 160B in 2024) - Revenue: Approximately $2.8-3.2 billion - Growth: Plateaued at 0-5% annually (versus 30%+ growth during 2020-2024) - Geography: Strong in Japan, Korea, UK; modest in US; growing in Asia

Nicotine Pouches (Velo, Grizzly, On brands): - Volume: Approximately 80-100 million cans annually by 2030 - Revenue: Approximately $900M-1.2 billion - Growth: 15-25% annually (strongest growth category) - Geography: Primarily US and Europe; emerging in Asia

Vaping/E-Cigarettes (Vuse brand): - Volume: Approximately 6-8 billion units annually (vapor equivalents) - Revenue: Approximately $1.5-2.0 billion - Growth: 5-10% annually (significant regulation creating headwinds) - Geography: US, Europe, emerging markets

Other Nicotine Products: - Oral nicotine, medicinal products, other formats - Combined revenue: ~$200-400 million - Growth: Varies by category

Total Smoke-Free Revenue (2030): Approximately $5.5-6.8 billion (20-25% of total revenue) Total Smoke-Free Operating Margin: Approximately 25-35% (lower than cigarettes due to higher manufacturing cost and brand development)

The Growth Shortfall Reality

By 2028-2029, it became clear that smoke-free products would not grow fast enough to replace cigarette profits:

2024 Expectations (CEO optimism): - By 2030, smoke-free would be 25-30% of revenue - By 2035, smoke-free would be 40-45% of revenue - By 2040, company would transition to majority smoke-free

2030 Reality (Sobering realization): - 2030: Smoke-free is 20-25% of revenue - 2035 trajectory: Smoke-free likely 30-35% of revenue (slower than hoped) - 2040 trajectory: Company likely still dependent on cigarette profits

Why the Shortfall: 1. Regulatory Headwinds: Vaping regulation, nicotine pouch restrictions, marketing limitations reduced growth potential 2. Consumer Behavior: Many smokers continued using cigarettes rather than switching to alternatives 3. Market Maturation: Initial growth in heated tobacco and pouches plateaued as early adopters were captured 4. Competition: Multiple competitors entered smoke-free space, fragmenting growth 5. Capital Inefficiency: Investments in smoke-free products generated lower returns than hoped

This realization meant the CEO's fundamental challenge—creating a successor business—remained unsolved.

SECTION 3: REGULATORY MANAGEMENT AND POLITICAL ENVIRONMENT

The Regulatory Squeeze

Running BAT in 2024-2030 meant constant engagement with hostile regulators:

Regulatory Actions (2024-2030):

Taxation: - Cigarette excise taxes increased in multiple markets - Minimum excise tax floors implemented in EU - Impact: Reduced cigarette affordability but supported pricing strategy (taxes enabled price increases attributed to regulation, not company greed)

Marketing Restrictions: - Plain packaging implemented in multiple new markets - Digital marketing restrictions - Point-of-sale display restrictions - Impact: Reduced marketing effectiveness but less existential than volume impact

Product Restrictions: - Menthol cigarette bans in EU and proposed in multiple countries - Vaping regulation created restrictions on flavoring - Nicotine pouch restrictions in specific markets - Impact: Reduced addressable market and product diversity

Age Restrictions: - Raising minimum purchase age in some markets - Restrictions on online sales - Impact: Limited market growth among youth (existing strategy anyway due to brand positioning)

Political and Social Environment

The political and social environment for tobacco companies in 2024-2030 deteriorated:

ESG and Institutional Investment: - Multiple large pension funds divested from tobacco - BlackRock, Vanguard, State Street reduced or eliminated tobacco holdings - Passive index funds (maintaining tobacco holdings) faced activist pressure - Impact: Reduced investor base but also stabilized remaining shareholders (true believers)

Public Health Advocacy: - Global health organizations positioned tobacco as public enemy - Advocacy for aggressive regulation - Impact: Political environment increasingly hostile

Company Response: Rather than fight regulation aggressively, the CEO adopted pragmatic approach: - Accept regulation as inevitable - Comply fully with regulations - Invest in regulated smoke-free products (regulation could constrain competitors while BAT controlled smoke-free) - Focus on markets where regulation was less restrictive (emerging markets in Asia, Africa, Latin America)

SECTION 4: THE DIVERSIFICATION QUESTION - STAY IN TOBACCO OR EXIT?

The Board Diversification Debate

Throughout 2024-2030, some board members questioned BAT's fundamental strategy: Should the company diversify beyond tobacco entirely?

The Diversification Case: - BAT's core business is declining - Rather than investing in uncertain smoke-free transition, why not acquire unrelated businesses (consumer health, pharmaceuticals, consumer goods)? - This would reduce dependence on tobacco, improve ESG profile, provide hedge against regulatory risk

The CEO's Counter-Argument: - BAT's strength is understanding nicotine consumers and consumer product distribution - Diversifying into unrelated businesses (pharmaceuticals, consumer health) would dilute focus and not leverage BAT's existing strengths - Success in unrelated categories would require expertise BAT lacked and would be expensive to acquire - Better strategy: deepen focus on nicotine business (cigarettes declining, but smoke-free alternatives growing) rather than exiting nicotine entirely

The Resolution: The board accepted the CEO's logic. Rather than diversifying away from nicotine, BAT committed to deeper smoke-free diversification—doubling down on nicotine delivery systems (heated tobacco, pouches, vaping) while gradually exiting traditional cigarettes.

This represented a strategic clarification: BAT was becoming a "nicotine company" rather than a "tobacco company." The company would remain in the addictive nicotine business, but in non-combustible forms.

SECTION 5: THE DIVIDEND COMMITMENT

Maintaining Investor Confidence Through Dividends

One of the CEO's most important and contentious decisions was the commitment to maintain or grow dividends despite declining volumes and uncertain smoke-free growth.

The Logic: 1. If BAT cut the dividend, income investors would immediately divest 2. Stock would crater, cost of capital would rise 3. Reduced capital availability would constrain smoke-free investments precisely when they were needed 4. Dividend commitment signaled confidence in smoke-free transition

The Execution: - 2024 dividend: ~440 pence per share (~4.0-4.5% yield) - 2025-2027: Maintained dividend in pence terms (modest growth in absolute terms) - 2028-2030: Slight dividend growth (modest, acknowledging business reality) - Simultaneously: Dramatically increased share buybacks

The Share Buyback Strategy: Rather than return all cash to shareholders through dividends, BAT used significant cash for share buybacks:

• 2024-2030 buybacks: Approximately $12-15 billion
• Effect: Reduced share count from ~2.1 billion shares (2024) to ~1.9 billion shares (2030)
• Result: EPS growth despite flat or declining earnings (buybacks reduced share count, supporting EPS)

The Math: - 2024 revenue: ~$35 billion - 2024 operating profit: ~$14 billion - 2024 net income: ~$8 billion - 2024 EPS: ~380 pence (based on 2.1B shares)

• 2030 revenue: ~$33-34 billion (declining)
• 2030 operating profit: ~$12.5 billion (declining)
• 2030 net income: ~$7-7.5 billion (declining)
• 2030 EPS: ~380-390 pence (stable/flat despite declining earnings, supported by buybacks)

This maintained investor confidence while the company navigated decline.

SECTION 6: ESG TENSIONS AND STAKEHOLDER MANAGEMENT

The ESG Contradiction

By 2030, BAT faced an uncomfortable contradiction: the company's traditional business (selling addictive nicotine products) was fundamentally at odds with modern ESG frameworks:

Environmental: Cigarettes have environmental impact (packaging, agriculture) but are not BAT's primary ESG challenge

Social: This is the core tension—selling addictive products that harm health directly contradicts social responsibility

Governance: BAT maintained strong governance practices, but governance of an inherently harmful business was ethically fraught

ESG Investor Response

Institutional investors responded in multiple ways:

Full Divestment: - Norwegian Government Pension Fund, some European pension funds fully divested - Reasoning: Tobacco sales fundamentally incompatible with ESG

Engagement and Partial Holdings: - Some investors maintained positions but demanded accelerated smoke-free transition - Engagement approach: pressure for change rather than divestment

Index Holding: - Passive index funds (S&P 500, FTSE) continued holding BAT because it remained index constituent - Passive holdings created tension—index managers didn't choose to hold tobacco but did so by index construction

CEO Response to ESG Challenge

The CEO took pragmatic approach:

1. Acknowledged Reality: BAT wouldn't qualify for ESG funds based on cigarette business, regardless of diversification efforts

2. Emphasized Transition: Marketing emphasized smoke-free transition and harm reduction narrative ("We're transitioning from cigarettes to smoke-free")

3. Accepted Divestment: Rather than fighting ESG critics, CEO accepted that some investors would divest and others would hold

4. Targeted Remaining Shareholders: Marketing increasingly focused on income investors who accepted tobacco business and growth investors convinced of smoke-free transition

SECTION 7: THE 2030 ASSESSMENT AND LONG-TERM TRAJECTORY

June 2030 Financial Position

By June 2030, the CEO had successfully maintained BAT as profitable, dividend-paying company:

Financial Metrics (June 2030): - Revenue: ~$33-34 billion (declining ~1-2% annually) - Operating profit: ~$12.5 billion (~37% operating margin) - Net income: ~$7.0-7.5 billion - Free cash flow: ~$5.5-6.0 billion - Dividend payment: ~$3.2-3.5 billion - Share price: ~3,200 pence (down from ~4,100 pence in 2024; decline reflected dividend-paying maturity + regulatory headwinds)

Operational Achievements: - Smoke-free products now 20-25% of revenue (up from 8-10% in 2024) - Smoke-free profit growing, but not fast enough to offset cigarette decline - Company remained profitable with strong cash generation - Dividend maintained, investor confidence held (though declined from 2024 peaks)

Assessment of Leadership

The CEO successfully managed decline:

Achievements: 1. Prevented panic divestment 2. Maintained profitability and cash generation 3. Invested meaningfully in smoke-free transition 4. Made difficult trade-offs transparent to investors 5. Balanced income investors, growth investors, and ESG critics

Unsolved Challenges: 1. Fundamental challenge remains unsolved—cigarette decline continues, smoke-free not growing fast enough 2. Long-term business model unclear 3. By 2040, if trends continue, company faces structural challenge unless smoke-free accelerates

The Finite Strategy

The CEO was essentially managing the orderly decline of a legacy business. This was neither failure nor success—it was appropriate management of unsolvable structural challenge.

By 2035-2040, BAT would face choice: 1. Successfully transition to majority smoke-free (unlikely given current trajectory) 2. Accept significantly lower profitability as cigarette business shrinks 3. Explore more fundamental transformation (acquisition, merger, exit)

The CEO bought time but didn't solve the fundamental problem.

SECTION 8: BROADER LESSONS ON MANAGING DECLINE

Lessons for Leaders of Declining Legacy Businesses

The BAT CEO's experience offers lessons for any legacy business confronting structural decline:

Lesson 1: Accept Reality, Don't Fight It Rather than fighting regulation or denial about decline, the CEO accepted decline as inevitable and focused on managing it responsibly.

Lesson 2: Generate Cash From Core Business While Investing in Transition The CEO milked the declining cigarette business for cash while investing significantly in smoke-free alternatives. This is the classic Coster-Benckiser playbook: harvest declining business, invest in growth alternatives.

Lesson 3: Maintain Stakeholder Confidence By maintaining dividends and transparent communication, the CEO prevented panic and capital flight. Investor confidence is critical when managing decline.

Lesson 4: Don't Over-Invest in Uncertain Alternatives Rather than betting the company on smoke-free (which remains uncertain), the CEO invested meaningfully but not recklessly. This prevented catastrophic losses if smoke-free failed.

Lesson 5: Avoid Diversification Into Unrelated Businesses Rather than diversifying away from nicotine, the CEO deepened focus on nicotine business with new products. This maintained focus and leveraged existing strengths.

Lesson 6: Prepare for Multiple Scenarios By 2030, the CEO was likely preparing for scenarios where smoke-free transition failed and more fundamental transformation became necessary by 2035-2040.

CONCLUSION

British American Tobacco's CEO between 2024-2030 navigated an existential challenge: managing a business fundamentally declining in its core market while attempting to transition to new products. By June 2030, the CEO had successfully maintained profitability and investor confidence while investing in smoke-free transition, though the fundamental challenge remained unsolved.

The BAT case demonstrates that leadership in legacy, declining businesses is less about innovation or growth, and more about: 1. Accepting reality 2. Generating cash from declining core 3. Investing carefully in uncertain alternatives 4. Maintaining stakeholder confidence 5. Preparing for transformation scenarios

The CEO couldn't prevent decline, but managed it responsibly and bought time for potential future transformation. This is not glamorous leadership, but it is necessary work.

STOCK IMPACT: THE BULL CASE VALUATION

Current Valuation (June 2030): - Stock price: ~3,200 pence - Dividend yield: 9.1% (vs. historical 7-8%)

Bull Case Valuation (2035): - Revenue: £28-32B (vs. £30-32B bear, but higher mix of profitable smoke-free) - Operating Margin: 38-42% (vs. 35-37% bear) - Dividend per Share: £0.48-0.54 (sustainable through smoke-free transition) - Stock Price: 3,400-3,800 pence (modest appreciation due to valuation model for declining company)

THE DIVERGENCE: BEAR vs. BULL COMPARISON TABLE

THE 2030 REPORT June 2030 Confidential

REFERENCES & DATA SOURCES

1. British American Tobacco Annual Report & SEC Form 20-F Filing, FY2029
2. Bloomberg Intelligence, "British American Tobacco: AI Enterprise Adoption & Competitive Impact," Q2 2030
3. McKinsey Global Institute, "Digital Transformation in UK Enterprises," March 2029
4. Bank of England, "Financial Stability and Corporate Sector Report," June 2030
5. Reuters UK, "UK Corporate Sector: Digital Disruption & Competitive Dynamics," Q1 2030
6. Gartner, "Enterprise AI Deployment in EMEA: ROI and Strategic Impact," 2030
7. OECD Economic Outlook, "UK Economic Growth and Corporate Investment," 2029
8. British American Tobacco Management Guidance, Q4 2029 Earnings Call Transcript & FY2030 Outlook
9. IMF Global Financial Stability Report, "UK Banking and Corporate Sector," April 2030
10. CBI/PwC, "UK Corporate Investment & Growth Survey," FY2029
11. Moody's, f"{company_name} Credit Rating Report," June 2030
12. S&P Global, "UK Corporate Sector Outlook," June 2030